Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases

Masahiro Nishibori, Shuji Mori, Hideo K. Takahashi

Research output: Contribution to journalReview articlepeer-review

60 Citations (Scopus)


High mobility group box-1 (HMGB1), a representative damage associated-molecular pattern (DAMP), has been reported to be involved in many inflammatory diseases. Several drugs are thought to have potential to control the translocation and secretion of HMGB1, or to neutralize extracellular HMGB1 by binding to it. One of these drugs, anti-HMGB1 monoclonal antibody (mAb), is highly specific for HMGB1 and has been shown to be effective for the treatment of a wide range of CNS diseases when modeled in animals, including stroke, traumatic brain injury, Parkinson's disease, epilepsy and Alzheimer's disease. Thus, anti-HMGB1 mAb not only is useful for target validation but also has extensive potential for the treatment of the above-mentioned diseases. In this review, we summarize existing knowledge on the effects of anti-HMGB1 mAb on CNS and PNS diseases, the common features of translocation and secretion of HMGB1 and the functional roles of HMGB1 in these diseases. The existing literature suggests that anti-HMGB1 mAb therapy would be effective for a wide range of CNS and PNS diseases.

Original languageEnglish
Pages (from-to)94-101
Number of pages8
JournalJournal of Pharmacological Sciences
Issue number1
Publication statusPublished - May 2019
Externally publishedYes


  • DAMP
  • Epilepsy
  • High mobility group box-1 (HMGB1)
  • Monoclonal antibody (mAb)
  • Neuroinflammation
  • Neuropathic pain
  • Stroke
  • TBI

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases'. Together they form a unique fingerprint.

Cite this